Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Healthcare Biotechnology
Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > Well We Will Soon Know Won’t We
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(2401)
•••
Comment by JDavenporton Aug 05, 2022 12:09pm
117 Views
Post# 34874368

RE:RE:RE:RE:RE:RE:RE:Well We Will Soon Know Won’t We

RE:RE:RE:RE:RE:RE:RE:Well We Will Soon Know Won’t WeLife, beenthere, is all about, "If this happens then these other things can happen."

Share prices do occasionally move up or down for no apparent reasons, but investment decisions always require an assessment of conditions. If good things happen then share prices will likely go up. If nothing happens then a share price will likely go down. If bad things happen then the share price will likely go down.

If you want certainty, buy a bag of chips and snarf them, because that's about as sure as anything can get.

So, what part of "if this then that" don't you get? Do you really not recognize that important consideration? Do you blindly follow stock forums without due diligence and careful consideration?

No wonder you consider yourself a victim of everything. You're too lazy to think for yourself.

I cackled out loud when you stated that nothing I have ever posted came true. You claim that you refuse to read my posts. That hardly qualifies you to say anything much about my posts.

You're just a mouth, beenthere, just a foolish old yapping mouth.

jd
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities